Clinical Trial Update: Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study [Phase 3]

View source ↗

Summary

Phase 3 multicenter randomized study evaluating induction and maintenance therapy with ustekinumab and upadacitinib in patients with refractory Crohn's disease;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• USTEKINUMAB (USTEKINUMAB)
• Upadacitinib (upadacitinib)

Snippet

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University | Conditions: Crohn's Disease Aggravated, Crohn's Disease in Remission | Phase 3 | Status: NOT_YET_RECRUITING